Patent application number | Description | Published |
20090010895 | Isolated cells and populations comprising same for the treatment of CNS diseases - An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype. | 01-08-2009 |
20090257987 | Method of generating dopamine-secreting cells - Methods of generating cells which secrete dopamine are disclosed. One method comprises incubating mesenchymal stem cells in a culture medium comprising brain derived neurotrophic factor (BDNF), wherein the culture medium comprises no more than 0.1 μM retinoic acid (RA). Another method comprises incubating mesenchymal stem cells in a culture medium comprising glial-derived neurotrophic factor GDNF, transforming growth factor β3 (TGFβ3) and retinoic acid (RA). Cells generated by the above-described methods are also disclosed as well as uses thereof. | 10-15-2009 |
20100021434 | Isolated Oligodendrocyte-Like Cells and Populations Comprising Same for the Treatment of CNS Diseases - Isolated human cells and populations thereof are provided comprising at least one oligodendrocyte phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an oligodendrocyte phenotype. Methods of generating and using same are also provided. | 01-28-2010 |
20100093600 | REGULATION OF NEUROTRANSMITTERS SEQUESTRATION AND RELEASE THROUGH MANIPULATION OF THE VESICULAR FUNCTIONS - A method of selecting an agent comprising a neuroprotecting activity is disclosed. The method comprises:
| 04-15-2010 |
20110212896 | PEPTIDES FOR THE TREATMENT OF OXIDATIVE STRESS RELATED DISORDERS - Isolated DJ-1 related peptides are disclosed and pharmaceutical compositions comprising same for treating oxidative stress-related disorder. | 09-01-2011 |
20120225822 | PEPTIDES FOR THE TREATMENT OF OXIDATIVE STRESS RELATED DISORDERS - Isolated DJ-1 related peptides are disclosed and pharmaceutical compositions comprising same for treating oxidative stress-related disorder. | 09-06-2012 |
20130123187 | PEPTIDES FOR THE REGULATION OF NEUROTRANSMITTER SEQUESTRATION AND RELEASE - A method of selecting an agent comprising a neuroprotecting activity is disclosed. The method comprises:
| 05-16-2013 |
20130236964 | METHODS, NUCLEIC ACID CONSTRUCTS AND CELLS FOR TREATING NEURODEGENERATIVE DISORDERS - A method of treating a neurodegenerative disorder is provided. The method is effected by administering to an individual in need thereof cells capable of exogenously regulatable neurotransmitter synthesis thereby treating the neurodegenerative disorder. | 09-12-2013 |
20130344041 | GENETICALLY MODIFIED MUSCLE CELLS WHICH EXPRESS NEUROTROPHIC FACTORS - An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed. | 12-26-2013 |
20140140968 | MESENCHYMAL STEM CELLS FOR THE TREATMENT OF CNS DISEASES - An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed. | 05-22-2014 |
20140154222 | ISOLATED CELLS AND POPULATIONS COMPRISING SAME FOR THE TREATMENT OF CNS DISEASES - An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype. | 06-05-2014 |
20140335059 | STEM CELL-DERIVED NEURAL CELLS FOR CELL THERAPY IN NEUROLOGICAL DISORDERS - The present invention provides methods and uses of neural cells differentiated from adult stem cells of the oral mucosa for cell therapy of neurological and psychiatric diseases and disorders. Methods for direction of differentiation of oral mucosal stem cells into neuronal or neuron supporting cells are also provided. | 11-13-2014 |
20150086517 | MESENCHYMAL STEM CELLS FOR THE TREATMENT OF CNS DISEASES - An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed. | 03-26-2015 |